8月8日，健康之路（02587）发布公告，预计截至2025年6月30日止六个月将录得溢利不少于600万元，而截至2024年同期则录得亏损约5728万元。该亏损主要由可转换可赎回优先股的优先权终止所产生的赎回负债账面值变动，以及上市筹备期间产生的开支所导致。
尽管出现溢利的增长，公告中提到，预计收入与2024年同期相比将减少约15%至18%，毛利将减少约8%至12%。收入减少的原因包括内容服务收入下降、价值医疗服务收入减少以及数字营销服务收入下降，后者主要受到经济下滑影响，导致客户减少广告及营销开支。公告中提醒股东及潜在投资者应审慎评估财务状况，实际中期业绩可能与公告所载资料有所不同。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.